TMT LLC operates in both the USA and India, with current R&D activities based in a temporary incubation facility at VCR Park, Visakhapatnam while a permanent lab is being built in Guntur, Andhra Pradesh. Guntur was chosen for its strategic advantages as the capital region, offering proximity to universities, research institutions, and leading hospitals, which enables seamless clinical collaborations and accelerates the translation of our research into real-world applications. This strategic positioning allows TMT LLC to leverage local expertise, driving forward the development of advanced immunotherapy and vaccine technologies.
Our organization specializes in pioneering innovative therapeutic platforms and advanced immunotherapies. We focus on developing cutting-edge vaccine solutions using minicircle-DNA technology, offering cost-effective and efficient alternatives to traditional plasmid-DNA vaccines. Our expertise extends to engineering genetically modified T cells, particularly CAR T cells, designed to target and overcome the challenges of treating solid tumors like ovarian and pancreatic cancers. Through our commitment to safety, efficacy, and accessibility, we aim to deliver next-generation therapies that provide new hope for patients battling aggressive cancers.
To revolutionize global healthcare by pioneering innovative vaccine and immunotherapy technologies,
leading the way towards safer, more effective treatments for complex and emerging diseases.
To transform the landscape of medical treatment through groundbreaking advancements in Minicircle-DNA vaccines and CAR T cell therapies, overcoming critical challenges in solid tumor treatment, and enhancing the safety and efficacy of next-generation therapies for the betterment of human health worldwide.
